XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3
License and Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 12, 2024
USD ($)
shares
Jul. 23, 2017
USD ($)
Apr. 30, 2018
USD ($)
shares
Sep. 30, 2024
USD ($)
Milestones
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Milestones
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Contract asset       $ 3,032,000   $ 3,032,000      
Revenue, excluding assessed tax       24,124,000 $ 24,144,000 69,252,000 $ 66,237,000    
Non-cash royalty revenue related to the sales of future royalties                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue, excluding assessed tax       15,731,000 $ 18,167,000 48,029,000 $ 50,860,000    
Bristol Myers Squibb Company                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Sale of stock shares repurchased | shares 8,300,000                
Sale of stock repurchased cash consideration $ 3,000,000                
Bristol Myers Squibb Company | Purchase Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Shares issued (in shares) | shares     8,284,600            
Sale of stock consideration received     $ 850,000,000            
Other Partner                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional payments for development milestones       $ 40,000,000   $ 40,000,000      
Nektar-358 | Eli Lilly                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing in Phase 2 development costs   75.00%              
Nektar-358 | Maximum | Eli Lilly And Company                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional development and regulatory milestones (up to)   $ 250,000,000              
Nektar 0165 | Biolojic Design Company [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Payable For Newdrug Investigle Milestone               $ 3,000,000  
Number of Milestone | Milestones       0   0      
Nektar 0165 | Maximum | Biolojic Design Company [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional payments for development milestones               35,000,000  
Payment For Development Milestones               $ 18,000,000  
Bristol Myers Squibb Collaboration Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Sale of stock shares repurchased | shares 8,300,000                
Sale of stock repurchased cash consideration $ 3,000,000                
Nektar's | Nektar-358                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Received upfront and milestone payment   $ 150,000,000              
Percentage of sharing in Phase 2 development costs   25.00%              
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront and milestone payments received from license agreements     $ 1,000,000,000            
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional payments for development milestones                 $ 50,000,000